Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Aksana K. Jones"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 3, Pp 138-145 (2019)
The use of model‐based drug development (MBDD) has been demonstrated to improve the efficiency of clinical trial design. However, MBDD complexity can limit its use, particularly early in clinical development. In this tutorial, a simple and generali
Externí odkaz:
https://doaj.org/article/80587ea9f63f437bb368f58da128977e
Autor:
Malcolm A. Young, Mathangi Gopalakrishnan, Eliford Ngaimisi, Aksana K. Jones, Céline M. Laffont
Publikováno v:
Clinical Pharmacokinetics
Background BUP-XR (a.k.a. RBP-6000 or SUBLOCADE™) is an extended-release subcutaneous buprenorphine formulation for the treatment of opioid use disorder. BUP-XR was designed to provide sustained buprenorphine exposure throughout the monthly dosing
Autor:
Aksana K. Jones, Paul J. Orchard, Christopher C. Dvorak, Hechuan Wang, Liusheng Huang, Vijay Ivaturi, Janel Long-Boyle
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, vol 25, iss 8
The primary objective of this work was to characterize the pharmacokinetics (PK) of systemic clofarabine (clo-fara) in pediatric allogeneic hematopoietic cell transplantation (HCT) recipients receiving either nucleoside monotherapy or a dual nucleosi
Autor:
Aksana K. Jones, Ahmed Salem, Walid M. Awni, Sven Mensing, Kevin J. Freise, Shekman Wong, Rod A. Humerickhouse, Doerthe Eckert
Publikováno v:
Clinical Pharmacokinetics. 56:515-523
Venetoclax is a selective, potent, first-in-class B-cell lymphoma-2 inhibitor that restores apoptosis in cancer cells and has demonstrated efficacy in a variety of hematological malignancies. The objective of this research was to characterize the rel
Autor:
Aksana K. Jones, Ahmed Salem, Shekman Wong, Suresh Agarwal, Rod A. Humerickhouse, Kevin J. Freise
Publikováno v:
The AAPS Journal. 18:1192-1202
Venetoclax (ABT-199/GDC-0199) is a selective, potent, first-in-class BCL-2 inhibitor that restores apoptosis in cancer cells and has demonstrated clinical efficacy in a variety of hematological malignancies. The objective of this analysis was to char
Autor:
Ahmed Salem, Aksana K. Jones, Graham P. Taylor, Kristine B. Patterson, Angela M. Nilius, Cheri E. Klein, Marilia Santini-Oliveira
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:400-408
Lopinavir-ritonavir is frequently prescribed to HIV-1-infected women during pregnancy. Decreased lopinavir exposure has been reported during pregnancy, but the clinical significance of this reduction is uncertain. This analysis aimed to evaluate the
Autor:
Maria Verdugo, Aksana K. Jones, Rajeev M. Menon, Ahmed Salem, Walid M. Awni, Kevin J. Freise, Rod A. Humerickhouse
Publikováno v:
Hematological oncology. 35(4)
Venetoclax is indicated at a dosage of 400 mg daily (QD) for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion who have received at least 1 prior therapy. Ongoing trials are evaluating venetoclax in combination with
Autor:
Ahmed Salem, Sari H. Enschede, Aksana K. Jones, David Hoffman, Martin Dunbar, Kevin J. Freise, Shekman Wong
Publikováno v:
Cancer chemotherapy and pharmacology. 78(4)
Venetoclax (ABT-199/GDC-0199) is a selective first-in-class B cell lymphoma-2 inhibitor being developed for the treatment of hematological malignancies. The aim of this study was to determine the potential of venetoclax to prolong the corrected QT (Q
Autor:
Doerthe Eckert, Rod A. Humerickhouse, Ahmed Salem, Walid M. Awni, Kevin J. Freise, Aksana K. Jones, Sven Mensing, Shekman L. Wong
Publikováno v:
Cancer Research. 76:2045-2045
Venetoclax is a selective, potent, orally bioavailable, small molecule, B-cell lymphoma-2 (Bcl–2) inhibitor that restores apoptosis in cancer cells. Clinical efficacy of venetoclax has been observed in a variety of hematological malignancies, inclu